Skip to main content
. 2021 Feb 11;21:23. doi: 10.1186/s12902-021-00689-7

Table 1.

Percentage of patients with Bullous pemphigoid and diabetes mellitus according to the type of gliptins

n % patients with BP % patients with type 2 diabetes
Patients with diabetes 76 67.3% 100%
Treatment with DPP-4is 52 46% 68%
Vildagliptin 11 9.7% 14.4%
Vildagliptin-Metformin 34 30.1% 44.73%
Linagliptin 3 2.7% 3.9%
Sitagliptin 1 0.9% 1.3%
Sitagliptin-Metformin 2 1.8% 2.6%
Alogliptin-Metformin 1 0.9% 1.3%
Saxagliptin 1 0.9% 13%

BP Bullous pemphigoid, DPP-4is Dipeptidyl-peptidase 4 inhibitors